Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …

EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib changed
dramatically the history of metastatic non-small cell lung cancer (NSCLC) harbouring EGFR …

Introduction Lung cancer is most common in older patients; despite this, older patients are
historically under-represented in clinical studies. Here we present data from GIDEON, a …

Objective The efficacy and safety of afatinib in elderly patients with EGFR-mutated non-small-
cell lung cancer (NSCLC) have not been evaluated. This study aimed to assess the efficacy …

Background and Objectives: Lung cancer remains the most common malignancy worldwide.
As the global population ages, the prevalence of epidermal growth factor receptor (EGFR) …

Background Lung cancer is most common among older individuals. However, polypharmacy
and comorbidities, which are also more common in older individuals, can limit treatment …

Background: The aim of this study was to assess the efficacy and safety of afatinib, an
epidermal growth factor receptor (EGFR) tyrosin kinase inhibitor (TKI), for elderly Japanese …

Background Afatinib is approved in the US, Europe, and several other regions for first-line
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …

Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are
standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer …

The elderly population with cancer is increasing worldwide. Currently, the median age at
lung cancer diagnosis is approximately 70 years. Clinicians are increasingly dealing with a …